JP2017537158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537158A5 JP2017537158A5 JP2017548325A JP2017548325A JP2017537158A5 JP 2017537158 A5 JP2017537158 A5 JP 2017537158A5 JP 2017548325 A JP2017548325 A JP 2017548325A JP 2017548325 A JP2017548325 A JP 2017548325A JP 2017537158 A5 JP2017537158 A5 JP 2017537158A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- thiazolo
- tetrahydrofuran
- hydroxy
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/093224 | 2014-12-08 | ||
| CN2014093224 | 2014-12-08 | ||
| CN2015086987 | 2015-08-14 | ||
| CNPCT/CN2015/086987 | 2015-08-14 | ||
| PCT/EP2015/078439 WO2016091698A1 (en) | 2014-12-08 | 2015-12-03 | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537158A JP2017537158A (ja) | 2017-12-14 |
| JP2017537158A5 true JP2017537158A5 (enExample) | 2020-04-30 |
| JP6817217B2 JP6817217B2 (ja) | 2021-01-20 |
Family
ID=54771116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548325A Active JP6817217B2 (ja) | 2014-12-08 | 2015-12-03 | ウイルス感染症の治療および予防のための３−置換された５−アミノ−６Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9441008B2 (enExample) |
| EP (1) | EP3230298B1 (enExample) |
| JP (1) | JP6817217B2 (enExample) |
| KR (2) | KR102557560B1 (enExample) |
| CN (2) | CN106164079B (enExample) |
| AU (1) | AU2015359692B2 (enExample) |
| BR (1) | BR112017011941B1 (enExample) |
| CA (1) | CA2963717C (enExample) |
| CL (1) | CL2017001426A1 (enExample) |
| CR (1) | CR20170237A (enExample) |
| DK (1) | DK3230298T3 (enExample) |
| EA (1) | EA038744B1 (enExample) |
| ES (1) | ES2864223T3 (enExample) |
| HR (1) | HRP20210454T1 (enExample) |
| HU (1) | HUE053704T2 (enExample) |
| IL (1) | IL251285B (enExample) |
| LT (1) | LT3230298T (enExample) |
| MA (1) | MA41134B1 (enExample) |
| MX (1) | MX379474B (enExample) |
| MY (1) | MY194002A (enExample) |
| PE (1) | PE20170679A1 (enExample) |
| PH (1) | PH12017501061A1 (enExample) |
| PL (1) | PL3230298T3 (enExample) |
| PT (1) | PT3230298T (enExample) |
| RS (1) | RS61612B1 (enExample) |
| SG (1) | SG11201704512PA (enExample) |
| SI (1) | SI3230298T1 (enExample) |
| TW (1) | TWI733656B (enExample) |
| UA (1) | UA124184C2 (enExample) |
| WO (1) | WO2016091698A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102557560B1 (ko) * | 2014-12-08 | 2023-07-20 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물 |
| MA52701A (fr) | 2015-03-16 | 2021-03-31 | Hoffmann La Roche | Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b |
| EP4001283A1 (en) * | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection |
| EP3317289B1 (en) * | 2015-06-30 | 2021-10-27 | F. Hoffmann-La Roche AG | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
| CN108430515B (zh) | 2015-10-29 | 2021-11-12 | 诺华股份有限公司 | 包含toll-样受体激动剂的抗体缀合物 |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| CN110167947B (zh) * | 2017-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 乙酸[(1S)-1-[(2S,4R,5R)-5-(5-氨基-2-氧代-噻唑并[4,5-d]嘧啶-3-基)-4-羟基-四氢呋喃-2-基]丙基]酯的固体形式 |
| CA3048768A1 (en) | 2017-01-06 | 2018-07-12 | F. Hoffmann-La Roche Ag | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds |
| US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| KR20200100113A (ko) | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US11059824B2 (en) | 2018-05-25 | 2021-07-13 | Primmune Therapeutics, Inc. | Substituted purines as TLR7 agonists |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2020257407A1 (en) | 2019-06-19 | 2020-12-24 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| IL293293A (en) | 2019-11-26 | 2022-07-01 | Primmune Therapeutics Inc | Tlr7 agonists |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| EP4081639A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| AU2020415307A1 (en) * | 2019-12-24 | 2022-06-09 | F. Hoffmann-La Roche Ag | Method of treating virus infection using a TLR7 agonist |
| EP4081217A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| JP2023536999A (ja) | 2020-08-05 | 2023-08-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎患者のオリゴヌクレオチド処置 |
| CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
| WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| IL312635A (en) | 2021-11-11 | 2024-07-01 | Hoffmann La Roche | Pharmaceutical combinations for treatment of hbv |
| CN121620516A (zh) * | 2023-08-08 | 2026-03-06 | 豪夫迈·罗氏有限公司 | 用于制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法 |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| TW202547866A (zh) | 2024-01-10 | 2025-12-16 | 丹麥商珍美寶股份有限公司 | Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法 |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| US5166141A (en) | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
| US5041426A (en) | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
| HUP0001186A3 (en) | 1996-10-16 | 2002-04-29 | Icn Pharmaceuticals Inc Costa | Purine l-nucleosides,analogs and pharmaceutical compositions thereof |
| EP1072607A3 (en) | 1996-10-16 | 2001-09-12 | ICN Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses therof |
| WO2005016235A2 (en) | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
| ES2342069T4 (es) | 2003-09-05 | 2011-01-26 | Anadys Pharmaceuticals, Inc. | Ligandos de tlr7 para el tratamiento de la hepatitis c. |
| CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| PL1824482T3 (pl) * | 2004-12-17 | 2014-07-31 | Anadys Pharmaceuticals Inc | 3,5-Dipodstawione oraz 3,5,7-tripodstawione związki 3H-oksazolo- oraz 3H-tiazolo[4,5-d]pirymidyn-2-onowe i ich proleki |
| SG152296A1 (en) | 2005-11-21 | 2009-05-29 | Anadys Pharmaceuticals Inc | Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one |
| AR061024A1 (es) | 2006-05-22 | 2008-07-30 | Novartis Ag | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. |
| WO2007150002A2 (en) * | 2006-06-22 | 2007-12-27 | Anadys Pharmaceuticals, Inc. | PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE |
| BRPI0714831A2 (pt) | 2006-07-18 | 2013-04-02 | Anadys Pharmaceuticals Inc | composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo |
| BRPI0717741A2 (pt) | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
| WO2009026292A1 (en) * | 2007-08-20 | 2009-02-26 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
| KR102557560B1 (ko) | 2014-12-08 | 2023-07-20 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 또는 예방을 위한 3-치환된 5-아미노-6H-티아졸로[4,5-d]피리미딘-2,7-다이온 화합물 |
| MA52701A (fr) | 2015-03-16 | 2021-03-31 | Hoffmann La Roche | Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b |
| EP4001283A1 (en) | 2015-05-12 | 2022-05-25 | F. Hoffmann-La Roche AG | Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection |
| EP3317289B1 (en) | 2015-06-30 | 2021-10-27 | F. Hoffmann-La Roche AG | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
-
2015
- 2015-12-03 KR KR1020177015128A patent/KR102557560B1/ko active Active
- 2015-12-03 KR KR1020237024143A patent/KR20230113824A/ko not_active Ceased
- 2015-12-03 ES ES15804128T patent/ES2864223T3/es active Active
- 2015-12-03 AU AU2015359692A patent/AU2015359692B2/en active Active
- 2015-12-03 MX MX2017007044A patent/MX379474B/es unknown
- 2015-12-03 EA EA201791011A patent/EA038744B1/ru unknown
- 2015-12-03 BR BR112017011941-2A patent/BR112017011941B1/pt active IP Right Grant
- 2015-12-03 JP JP2017548325A patent/JP6817217B2/ja active Active
- 2015-12-03 CN CN201580018026.1A patent/CN106164079B/zh active Active
- 2015-12-03 RS RS20210297A patent/RS61612B1/sr unknown
- 2015-12-03 CN CN201710845723.5A patent/CN107445980B/zh active Active
- 2015-12-03 CR CR20170237A patent/CR20170237A/es unknown
- 2015-12-03 SG SG11201704512PA patent/SG11201704512PA/en unknown
- 2015-12-03 PL PL15804128T patent/PL3230298T3/pl unknown
- 2015-12-03 MY MYPI2017702051A patent/MY194002A/en unknown
- 2015-12-03 LT LTEP15804128.5T patent/LT3230298T/lt unknown
- 2015-12-03 WO PCT/EP2015/078439 patent/WO2016091698A1/en not_active Ceased
- 2015-12-03 EP EP15804128.5A patent/EP3230298B1/en active Active
- 2015-12-03 MA MA41134A patent/MA41134B1/fr unknown
- 2015-12-03 PT PT158041285T patent/PT3230298T/pt unknown
- 2015-12-03 UA UAA201706823A patent/UA124184C2/uk unknown
- 2015-12-03 PE PE2017000551A patent/PE20170679A1/es unknown
- 2015-12-03 CA CA2963717A patent/CA2963717C/en active Active
- 2015-12-03 HU HUE15804128A patent/HUE053704T2/hu unknown
- 2015-12-03 US US14/958,619 patent/US9441008B2/en active Active
- 2015-12-03 DK DK15804128.5T patent/DK3230298T3/da active
- 2015-12-03 HR HRP20210454TT patent/HRP20210454T1/hr unknown
- 2015-12-03 SI SI201531553T patent/SI3230298T1/sl unknown
- 2015-12-07 TW TW104140978A patent/TWI733656B/zh active
-
2016
- 2016-07-11 US US15/207,338 patent/US10040815B2/en active Active
-
2017
- 2017-03-20 IL IL251285A patent/IL251285B/en unknown
- 2017-06-05 CL CL2017001426A patent/CL2017001426A1/es unknown
- 2017-06-07 PH PH12017501061A patent/PH12017501061A1/en unknown
-
2018
- 2018-07-02 US US16/025,170 patent/US10618929B2/en active Active
-
2020
- 2020-04-13 US US16/847,552 patent/US11180525B2/en active Active